China Warns on Stem Cell Anti-Aging Shots, Dengue Risk Rises
China’s National Health Commission (NHC) has issued a stern warning against unproven stem cell “anti-aging injections,” while the country’s disease control authorities simultaneously cautioned that imported cases of dengue fever and chikungunya are raising the risk of local outbreaks. The dual announcements, made on consecutive days, signal a coordinated public health push as China enters the peak summer season.
Stem Cell Warning: ‘Do Not Believe the Hype’
At a press conference on July 15, NHC spokesperson Hu Qiangqiang warned the public not to fall for marketing claims surrounding so-called stem cell “anti-aging injections,” or “不老针” (bù lǎo zhēn). According to People’s Daily, Hu stated that illegal institutions and individuals have been exploiting public anxiety about disease treatment and health preservation to promote unapproved stem cell products, claiming they can “reverse aging,” “repair organs,” and “cure chronic diseases.”
Hu emphasized three key points under the newly implemented State Council Decree No. 818 — the “Regulations on the Management of Clinical Research and Clinical Translation Application of Biomedical New Technologies,” which took effect on May 1, 2026:
- All stem cell clinical research must be registered, and clinical translation applications must receive formal approval.
- Stem cell treatments may only be performed by qualified professional medical institutions — beauty salons, health centers, and cell technology service companies are prohibited from conducting such procedures.
- Unapproved stem cell products still in the research phase cannot be used clinically or sold to patients.
The public was encouraged to report violations to local authorities or via the 12345 hotline.
A Growing Gray Market
The warning comes more than two months after Decree No. 818 took effect, suggesting that enforcement remains a challenge. A China Newsweek investigation published on June 15 found that many operators of unapproved stem cell treatments have moved their businesses underground, accepting only regular customers to avoid detection. Reports indicate that some clinics continue to charge hundreds of thousands of yuan (tens of thousands of US dollars) per treatment, often targeting wealthy clients seeking anti-aging solutions.
Industry analysts cited by Guangming Online have described the new regulations as ending a “20-year gray ecology” in China’s cell therapy market, shifting the industry from “barbaric growth” to a “compliance-first” model.
Dengue and Chikungunya: A Growing Threat
On July 16, the National Disease Control and Prevention Administration held its own press conference, where researcher Li Jiandong of the Chinese Center for Disease Control and Prevention (China CDC) warned that the risk of local outbreaks of dengue fever and chikungunya is rising due to imported cases and cross-provincial transmission, as reported by CCTV News.
Li cited several converging factors:
- Global spread: Both mosquito-borne diseases are spreading widely across tropical and subtropical countries.
- Climate change: Rising global temperatures are expanding the habitat of Aedes vector mosquitoes.
- Increased travel: Post-pandemic cross-border travel is rising, increasing the risk of imported cases.
- Summer conditions: Heat and rainfall create favorable conditions for mosquito breeding, while summer vacation travel amplifies transmission risks.
Policy Upgrades
In response, Chinese authorities have implemented significant policy changes. Since April 1, 2026, chikungunya has been classified as a Category B infectious disease under Chinese law — the same category as COVID-19, AIDS, and SARS — requiring mandatory case reporting and isolation. The National Disease Control Administration and the NHC jointly issued the “Dengue Fever and Chikungunya Prevention and Control Plan (2026 Edition),” promoting integrated prevention of both diseases through a four-pronged strategy: law-based control, inter-agency coordination with customs and immigration authorities, early detection and containment, and public health campaigns.
Analysis and Outlook
The timing of these two announcements — on consecutive days from two related government bodies — reflects a coordinated approach to summer public health risks. The stem cell warning reinforces the new regulatory framework established by Decree No. 818, signaling that authorities are actively monitoring illegal operators. Meanwhile, the dengue and chikungunya alert highlights the growing intersection of climate change, global travel, and infectious disease risk.
Southern provinces including Guangdong, Yunnan, and Hainan — which have historically experienced periodic dengue outbreaks — are expected to be on highest alert. The reclassification of chikungunya as a Category B disease marks a significant escalation in official concern, and the new joint prevention plan aims to detect and contain outbreaks early.
As summer travel peaks and mosquito season intensifies, Chinese health authorities are urging the public to exercise caution — both in avoiding unproven medical treatments and in taking preventive measures against mosquito-borne diseases.